Research programme: microbiome therapeutics - Seres Therapeutics
Latest Information Update: 22 Mar 2017
At a glance
- Originator Seres Therapeutics
- Developer Massachusetts General Hospital; Seres Therapeutics; University of Pennsylvania
- Class Bacteria
- Mechanism of Action Bacteria replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Inflammatory bowel diseases; Metabolic disorders; Metabolic syndrome